article thumbnail

My Salon Suite Expands Portfolio with Acquisition of Mera Salon Suites

Skin Inc

The acquisition comes amid My Salon Suite's ongoing strategy for growth, which resulted in more than 40 franchise agreements and 43 store openings for the brand in 2023.

article thumbnail

Incyte to Present Numerous Studies at EADV 2023

Dermatology Times

Late-breaking data, oral presentations, and ePosters from Incyte’s dermatology portfolio will be presented in Berlin, Germany, October 11-14.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Dr Godfrey Town Ph.D re-Certifies as Laser Protection Adviser

Online Laser Training

Our Online Laser Training International Programme Director, Dr Godfrey Town has been re-certified from 1st May 2023 by RPA 2000 for a further five years to act as a Laser Protection Adviser (LPA) and Dr Town holds this for medical, research and teaching.

article thumbnail

Dr Godfrey Town Ph.D re-Certifies as Laser Protection Adviser

Online Laser Training

Our Online Laser Training International Programme Director, Dr Godfrey Town has been re-certified from 1st May 2023 by RPA 2000 for a further five years to act as a Laser Protection Adviser (LPA) and Dr Town holds this for medical, research and teaching.

article thumbnail

Expanding Your Practice in 2023: The Top 5 Non-Invasive Treatments Professionals Should Know

Aesthetic Advancements Institute (AAI)

For practitioners keen on expanding their portfolio and offering cutting-edge procedures, understanding the year’s top tweakments is essential. Dermal Fillers: A Renaissance Beyond Lips Though dermal fillers are often linked to plump lips, 2023 sees a broader application: sculpting high cheekbones and defining chins.

article thumbnail

FDA Nod for Ustekinumab Biosimilar

The Dermatology Digest

market, is an important milestone on our pathway to consistently broadening our biopharma portfolio in the U.S. In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. and worldwide.

article thumbnail

FDA Nod for PYZCHIVA (ustekinumab-ttwe), Samsung Bioepis’ Stelara Biosimilar

The Dermatology Digest

Samsung Bioepis and Sandoz entered into a commercialization agreement for SB17 (PYZCHIVA) in September 2023 for the US, Canada, European Economic Area (EEA), Switzerland, and United Kingdom (UK). PYZCHIVA, developed by Samsung Bioepis, will be commercialized by Sandoz in the United States.